Citation Impact
Citing Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
2015 Standout
Aquaporin-4 antibody–negative neuromyelitis optica
2013
Pathologic heterogeneity persists in early active multiple sclerosis lesions
2014
Non-muscle myosin II takes centre stage in cell adhesion and migration
2009 Standout
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis
2008 Standout
Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis
2007
Myasthenia Gravis
2016 Standout
Effects of Flavonoids and other Polyphenols on Inflammation
2011 Standout
Neurofilament light chain as a biomarker in neurological disorders
2019 Standout
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
2008 Standout
Guillain-Barré syndrome
2016 Standout
Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome
2015
Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
2017
Repertoire of microglial and macrophage responses after spinal cord injury
2011 Standout
Cytokine Secretion Pattern in Treatment of Lymphocytes of Multiple Sclerosis Patients with Fumaric Acid Esters
2011
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis
2012
Immunopathology of multiple sclerosis
2015 Standout
Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms
2007
Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
2015
The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain
2008
Neuromyelitis optica spectrum disorders associated with other autoimmune diseases
2014
The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination
2004
Aquaporin 4 and neuromyelitis optica
2012
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
2015
Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis
2017
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation
2006
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
The history of neuromyelitis optica
2013
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies
2014
Aquaporin‐4 Antibodies (NMO ‐IgG ) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature
2013
TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton
2008
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
2013
Multiple Sclerosis
2018 Standout
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
2014
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
2012
Nogo-A and Nogo Receptor Expression in Demyelinating Lesions of Multiple Sclerosis
2005
Diagnosis and therapy of acute disseminated encephalomyelitis and its variants
2015
The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis
2006
NMDA receptor antibodies associated with distinct white matter syndromes
2014
Physiology of Microglia
2011 Standout
Works of Rainer Ehling being referenced
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
2011
Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments
2006
Multiple Sclerosis – Established and Novel Therapeutic Approaches
2010
Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders
2003
Increased serum levels of soluble CD14 indicate stable multiple sclerosis
2006
Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases
2010
Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis
2005
Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia
2006